Risk Based Verification 2021 - Risk Based Verification and/or Validation to meet US FDA CGMP and ISO 13485 Requirements
Topics/Call fo Papers
Webinar for a discussion of the webinar how to review a company's Validation Master Plan for major cGMP deficiencies. Review hazard and risk management tools per ISO 14971 and ICH Q9.
FDA Warning Letters and high-profile recalls indicate major cGMP deficiencies in device and pharma companies on both sides of the Atlantic. One major failing is lack of sufficient or targeted risk-based V&V planning.
Verification or Validation -- Current regulatory expectations.
The Master Validation Plan and the Individual V&V Plan.
Product V&V versus Process / Equipment V&V versus QMS V&V
Speaker:
John E. Lincoln is Principal of J. E. Lincoln and Associates LLC, a consulting company, with over 32 years experience in U.S. FDA-regulated industries, 18 of which as a full time independent FDA-
FDA Warning Letters and high-profile recalls indicate major cGMP deficiencies in device and pharma companies on both sides of the Atlantic. One major failing is lack of sufficient or targeted risk-based V&V planning.
Verification or Validation -- Current regulatory expectations.
The Master Validation Plan and the Individual V&V Plan.
Product V&V versus Process / Equipment V&V versus QMS V&V
Speaker:
John E. Lincoln is Principal of J. E. Lincoln and Associates LLC, a consulting company, with over 32 years experience in U.S. FDA-regulated industries, 18 of which as a full time independent FDA-
Other CFPs
- Pharmaceutical Compressed Air - Quality GMP Requirements - What you need to know to meet FDA and International Quality Standards
- Guidance for Businesses and Employers to Plan and Respond to Coronavirus Disease (COVID-19)
- Your Organization Culture: What Stays the Same? What Changes During and After Covid-19?
- The Income Statement - What a Banker Can Learn About a Borrower from Its Profit and Loss Statement
- W-9s and 1099s
Last modified: 2021-01-14 22:06:24